查詢結果
共有 30 筆符合條件的資料
序號 | 篇名 | 作者 | 日期 | 期刊 |
---|---|---|---|---|
1 | 由歐盟孤兒藥案件談競爭法與藥品超額定價問題【醫法新論】 EU Orphan Drug Cases and Tackling Excessive Drug Pricing by the Enforcement of Competition Law |
魏杏芳 | 2023/06 | 月旦醫事法報告 |
2 | 藥師調劑處方跨行政區交付藥品行為之適法性【月旦時論】 Legality of Delivering Drugs across Administrative Regions after Dispensing Prescriptions |
余萬能 | 2021/11 | 月旦醫事法報告 |
3 | COVID-19疫苗及藥品之緊急使用授權【醫事法學教室】 Emergency Use Authorization for Vaccines and Medicines During the COVID-19 Pandemic |
余萬能 | 2021/07 | 月旦醫事法報告 |
4 | 藥品智財、管制與衛生治理【月旦時論】 Intellectual Property, Drug Regulatory, and Health Governance |
鄒孟珍、蔡昀廷、劉汗曦 | 2021/05 | 月旦醫事法報告 |
5 | 藥師調劑及販賣藥品之說明義務【醫事法學教室】 The Pharmacist’S Obligations of Information during Dispensing and Selling Medicines |
余萬能 | 2021/03 | 月旦醫事法報告 |
6 | 藥品不良反應通報處理案例剖析:嚴重藥品不良反應通報案件【實務講座】 Reporting of Adverse Drug Reactions in Taiwan: A Serious Adverse Drug Reaction Report |
財團法人藥害救濟基金會 | 2021/02 | 月旦醫事法報告 |
7 | 臺灣藥品早期臨床試驗──規範與現況【本期企劃】 Regulations and Status of Early Clinical Trials of Medicinal Products in Taiwan |
陳映潔、張連成、潘香櫻 | 2020/11 | 月旦醫事法報告 |
8 | 從SARS到COVID-19看臺灣於藥品專利強授權之進程【特別企劃】 The Development of Compulsory Licensing of Medicine from SARS to COVID-19 in Taiwan: An Expectation to the Legal State |
張哲倫 | 2020/06 | 月旦醫事法報告 |
9 | 藥品研發與近用──從藥事法專利連結專章及資料專屬權談起【本期企劃】 Innovation and Access to Medicine: Implementation of Patent Linkage and Data Exclusivity in Taiwan |
李素華 | 2019/12 | 月旦醫事法報告 |
10 | 臺灣藥品專利訴訟之觀察──兼論專利連結制度的影響【本期企劃】 Observation of Pharmaceutical Patent on Patent Infringement Litigation in Taiwan: Also on the Impact of the Patent Linkage System |
呂紹凡 | 2019/12 | 月旦醫事法報告 |